^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MDNA132

    i
    Other names: MDNA132, MDNA-132, MDNA 132
    Associations

    News

    Trials
    Company:
    Medicenna
    Drug class:
    IL-13 antagonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    Characterization of MDNA132, an IL-13 decoy receptor selective superkine for targeted delivery of immunotherapies to the tumor microenvironment (AACR 2023)
    MDNA132 is an engineered IL13Rα2 selective superkine that accumulates in TME of IL13Rα2 expressing tumors in mice. MDNA109FEAA-Fc-MDNA132 and anti-PD1-MDNA132 retain their respective receptor binding profile, IL2R agonism and PD1/PDL1 blockade illustrating the versatilityof MDNA132 BiSKIT platform for targeted delivery of a broad range of therapeutic and/or immune-modulatory agents to tumors overexpressing the IL13α2 decoy receptor.
    PD(L)-1 Biomarker • IO biomarker
    |
    IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • IL13 (Interleukin 13)
    |
    IL13RA2 expression
    |
    MDNA132
    2years
    MDNA132 is an IL-13 Superkine selective to IL-13Rα2 with broadpotential for delivery of immunotherapies to the tumormicroenvironment (AACR-NCI-EORTC 2022)
    MDNA132-based BiSKITs retain receptor binding profileand biological function of both MDNA132 and the fusion partner. MDNA132localizes preferentially to IL-13Rα2 tumors in mice. These data highlight theversatility of MDNA132 and its potential to localize delivery of immunotherapeutics to the TME of cancers expressing IL-13Rα2.
    IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • IL13 (Interleukin 13) • IL4 (Interleukin 4)
    |
    MDNA132